Newbury Pharmaceuticals AB logo

Newbury Pharmaceuticals AB (P52)

Market Open
18 Aug, 13:26
XFRA XFRA
0. 17
-0
-2.071%
- Market Cap
- P/E Ratio
- Div Yield
150 Volume
0 Eps
0.17
Previous Close
Add Transaction
Day Range
0.17 0.22
Year Range
0.02 0.29
Want to track P52 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

P52 trading today lower at €0.17, a decrease of -2.071% from yesterday's close, completing a monthly increase of 9.6027% or €0.01. Over the past 12 months, P52 stock gained 63.8614%.
P52 is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on one exchange.

P52 Chart

Newbury Pharmaceuticals AB (P52) FAQ

What is the stock price today?

The current price is €0.17.

On which exchange is it traded?

Newbury Pharmaceuticals AB is listed on XFRA.

What is its stock symbol?

The ticker symbol is P52.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Newbury Pharmaceuticals AB ever had a stock split?

No, there has never been a stock split.

Newbury Pharmaceuticals AB Profile

Specialty Retail Industry
Consumer Discretionary Sector
Mr. Karl Alexius Tiger Karlsson CEO
XFRA Exchange
SE0015244884 ISIN
SE Country
8 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Newbury Pharmaceuticals AB (publ) represents a progressive player in the pharmaceutical industry, distinguished by its hybrid operational model tailored specifically for the Swedish and broader Scandinavian markets. Established in 2020 with its headquarters nestled in Lund, Sweden, the company has rapidly made its mark by focusing on the development and distribution of pharmaceutical products across several critical treatment categories. With a mission to address some of the most challenging health issues, Newbury Pharmaceuticals integrates scientific innovation with strategic market practices to cater to the needs within oncology, rare diseases, neurology, among other areas.

Products and Services

  • Oncology
  • Within the realm of oncology, Newbury Pharmaceuticals endeavors to provide groundbreaking treatments for cancer. The company prioritizes the development and distribution of medications that promise to improve the outcome and quality of life for patients grappling with various types of cancer. By focusing on innovation and accessibility, their oncology portfolio reflects a commitment to meeting the urgent needs of the affected patient populations.

  • Rare Diseases
  • Recognizing the unique challenges faced by individuals diagnosed with rare diseases, Newbury Pharmaceuticals dedicates a significant portion of its research and development efforts to discovering treatments for these lesser-known, yet profoundly impactful conditions. Through targeted therapy options and patient support programs, the company aims to bridge the treatment gap and provide hope for those with limited options.

  • Neurology
  • The neurology segment is another critical focus area for Newbury Pharmaceuticals, where it aims to address a spectrum of neurological disorders through innovative pharmaceutical solutions. The company's dedication to advancing neurology encompasses efforts to understand the complexities of the nervous system, with the goal of offering treatments that enhance life quality for individuals afflicted by neurological conditions.

  • Other Treatment Products
  • Apart from its specialized focus on oncology, rare diseases, and neurology, Newbury Pharmaceuticals also extends its product portfolio to include a variety of other therapeutic areas. This diversification enables the company to meet a broad range of healthcare needs, ensuring a comprehensive approach to promoting health and well-being across different patient populations.

Contact Information

Address: Medicon Village, Lund, Sweden, 223 81
Phone: 46 46 12 11 20